Yes, because at last, and I am a long-suffering MSB shareholder, some MSB shareholders have to of course beat their chest on a whiff of MSB outperformence, not thinking perhaps a floating tide for stem cell approvals at the FDA might float all struggling boats.
How ironic that CYP closed up 7% the next trading day after the fool's comments. Perhaps he can work out that 3 patients having enrolled given EU only got cleared in late March and the first patient early March, is actually just fine in the context of a small 60 patient trial and the company's guided time frame.
Oh look, they actually said as much in the 4C release...
"During the quarter, the first patient was enrolled in this trial (announced 5 March), and subsequently regulatory and ethics approval was secured in the European Union (announced 20 March). By the end of the quarter, a total of 14 clinical centres were open for recruitment, across Australia, the USA and Turkey, with most of the remaining centres expected to open during Q2 2024. Patient enrolment is approximately 5% complete, which is broadly consistent with the Company’s previously announced recruitment projection, under which completion of enrolment is anticipated by the end of calendar year 2024, with primary results expected in H2 2025."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)